Compass Therapeutics, Inc.

1.87 USD
+0.07 (+3.89%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Compass Therapeutics, Inc. stock is up 29.86% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 February’s closed higher than January.

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trials for colorectal and ovarian cancer.